Patients’ access to rare neuromuscular disease therapies varies across US private insurers

BACKGROUND: The extent to which different US private insurers require their enrollees to meet the same coverage criteria before gaining access to treatment is unclear. Our objective was to scrutinize the patient access criteria imposed by US private insurers for a set of rare neuromuscular disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: Margaretos, Nikoletta M., Bawa, Komal, Engmann, Natalie J., Chambers, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817582/
https://www.ncbi.nlm.nih.gov/pubmed/35123543
http://dx.doi.org/10.1186/s13023-022-02182-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817582/
https://www.ncbi.nlm.nih.gov/pubmed/35123543
http://dx.doi.org/10.1186/s13023-022-02182-3

Ejemplares similares